Brussels: The European Union edged closer this week to a landmark law on critical medicines, as officials confirmed that the provisional deal struck by Parliament and Council in May now awaits final legal-linguistic sign-off before formal adoption. The Critical Medicines Act aims to end the chronic shortages that have left pharmacies across the bloc rationing everyday drugs.
Negotiators reached the provisional agreement in the early hours of 12 May, capping a year of talks over how far Europe should go to reclaim its pharmaceutical supply chains. The Council and Parliament announced the deal as a decisive step toward what lawmakers call pharmaceutical sovereignty.
The numbers behind the push are stark. Between January 2022 and October 2024, the EU ran critically short of 136 medicines, from antibiotics to cancer treatments. The Commission first tabled the proposal in March 2025, arguing that Europe’s reliance on a handful of overseas suppliers, chiefly in Asia, had become a strategic liability.
The new rules attack the problem on several fronts. They push member states to diversify supply chains, reward companies that manufacture critical medicines and their active ingredients inside the EU, and make it easier for governments to buy jointly. Co-legislators lowered the threshold for triggering a joint procurement request from nine countries to five, a change that should let smaller states band together far more quickly.
Supporters say domestic manufacturing incentives sit at the heart of the reform. By steering public money toward EU-based production of active pharmaceutical ingredients, Brussels hopes to rebuild a manufacturing base that decades of offshoring hollowed out. The Commission has paired the law with a list of critical medicines and a broader push to modernise the bloc’s pharmaceutical legislation.
Critics counter that security will not come cheap. Building redundancy into supply chains and paying a premium for European-made ingredients raises costs, and industry groups warn that without sustained funding the incentives may fall short. Some smaller manufacturers fear the compliance burden could squeeze them out rather than draw them in.
The timing still carries risk. Officials expect the agreed text to appear in the Official Journal toward the end of 2026, with the application date yet to be confirmed. That leaves a window in which fresh shortages could test public patience before the law bites.
For patients, the promise is straightforward: fewer empty shelves and fewer frantic calls between pharmacies hunting for a missing prescription. Whether the Critical Medicines Act delivers that will depend on how aggressively member states use the tools it hands them. The Council’s policy overview sets out the next procedural steps.
What comes next is endorsement by both institutions, then formal adoption. The harder test follows: turning legal text into real factories, stockpiles, and reliable deliveries. Europe has named the disease. The cure, as ever, will take time and money.
